Evidence map›Paper›PMID 29974836›Full record

ArticleEpidemiology and infection2018

Prevalence of hepatitis E in liver transplant recipients in Greece.

Ε Sinakos, G Gioula, Ch Liava, A Papa, E Papadopoulou, E Tsakni, I Fouzas, E Akriviadis

Open access · bronzeAbstract read
In one paragraph

Article in Epidemiology and infection, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Hepatitis E virus screening in solid organ transplant recipients: prevalence and implications for implementation, Spain, 2021 to 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Ε Sinakos4th Medical Department,Aristotle University of Thessaloniki, Hippokratio Hospital,Thessaloniki,Greece.ORCID 0000-0003-0923-050X
G GioulaMicrobiology Department,Medical School, Aristotle University of Thessaloniki,Thessaloniki,Greece.
Ch Liava4th Medical Department,Aristotle University of Thessaloniki, Hippokratio Hospital,Thessaloniki,Greece.
A PapaMicrobiology Department,Medical School, Aristotle University of Thessaloniki,Thessaloniki,Greece.
E PapadopoulouMicrobiology Department,Medical School, Aristotle University of Thessaloniki,Thessaloniki,Greece.
E TsakniDepartment of Transplant Surgery,Aristotle University of Thessaloniki, Hippokratio Hospital,Thessaloniki,Greece.
I FouzasDepartment of Transplant Surgery,Aristotle University of Thessaloniki, Hippokratio Hospital,Thessaloniki,Greece.
E Akriviadis4th Medical Department,Aristotle University of Thessaloniki, Hippokratio Hospital,Thessaloniki,Greece.
Aristotle University of Thessaloniki · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis E virus (HEV) is a well-known cause of acute hepatitis. Immunocompromised subjects, including liver transplant recipients, are considered to be at risk for HEV infection, which occasionally follows a chronic course. The diagnosis of HEV infection in these patients must be based on HEV RNA testing, as serology has variable performance. The aim of this study was to assess the prevalence of HEV infection in liver transplant recipients in Greece by means of HEV RNA testing. Liver transplant recipients followed in the sole transplant centre in Greece were prospectively included. HEV RNA was detected by real-time RT-PCR. Positive samples were further analysed using a nested reverse transcription RT-PCR kit, which amplifies a 137-nucleotide sequence within the ORF2/ORF3 overlapping region to detect the HEV genotype and perform phylogenetic analysis. The mean age of the included patients (n = 76) was 54 years. The most common indication for liver transplantation was viral hepatitis (57%). The majority of the patients (75%) received a calcineurin inhibitor as part of their immunosuppressive regimen and had normal liver enzymes. HEV RNA was found positive in only 1/76 (1.3%) patient. Phylogenetic analysis showed that the sequence clustered into the HEV genotype 3 clade. This patient experienced an acute hepatitis flare, which nonetheless did not become chronic. The prevalence of HEV infection in liver transplant recipients in Greece is similar (1.3%) to that reported previously in other countries. Transplant physicians should be aware of this condition and its associated consequences.

Indexed as

FemaleGreeceHepatitis EHepatitis E virusHumansLiver TransplantationMaleMiddle AgedPhylogenyPrevalenceProspective StudiesRNA, ViralSequence Analysis, RNATransplant RecipientsViral ProteinsORF2 protein, Hepatitis E virusORF3 protein, Hepatitis E virusRNA, ViralViral ProteinsHepatitis Eimmunosuppressionprevalencetransplantation

Identifiers

PMID29974836
PMCPMC9507950
OpenAlexW2868794325

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.